Welcome to our dedicated page for Aardvark Therapeutics SEC filings (Ticker: AARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aardvark Therapeutics, Inc. (Nasdaq: AARD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Aardvark uses forms such as Form 8-K to report material events, clinical and scientific updates, and quarterly financial results related to its pipeline of small-molecule therapies for Prader-Willi Syndrome and metabolic diseases.
Recent AARD filings include Form 8-K reports furnishing quarterly financial results and business updates, such as results for periods ended June 30 and September 30, along with commentary on research and development spending, general and administrative expenses, and cash, cash equivalents, and short-term investments. These filings often incorporate press releases as exhibits, giving investors a consolidated view of the company’s financial condition and development plans.
Aardvark also files 8-Ks under Items 7.01 and 8.01 to describe clinical and scientific milestones, including presentations at ObesityWeek, new preclinical data on ARD-201 and WE-868, and alignment with the U.S. Food and Drug Administration on protocol amendments to the Phase 3 HERO trial of ARD-101 in Prader-Willi Syndrome. Other 8-Ks document investor webinars reviewing ARD-101 and ARD-201 programs and provide access to slide presentations used in those events.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on topics such as clinical trial progress, regulatory interactions, financial trends, and risk factor references. Users can monitor new 8-Ks and, when available, 10-Q and 10-K reports to follow how Aardvark describes its pipeline, capital resources, and development risks over time.
For those researching AARD stock, this filings page offers a structured way to review the company’s official disclosures, including material events, scientific data announcements, and financial reporting, with tools that make complex SEC documents easier to interpret.
Aardvark Therapeutics, Inc. director, chief executive officer, and 10% owner Lee Tien-Li reported receiving a stock option grant. On February 9, 2026, they were granted an option to buy 203,851 shares of common stock at an exercise price of $13.48 per share.
According to the vesting terms, one quarter of the option will vest on February 9, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, contingent on continued service. After this grant, 203,851 derivative securities are held directly.
Aardvark Therapeutics, Inc. announced U.S. Institutional Review Board approval of an amended protocol for its Phase 3 HERO trial of lead candidate ARD-101 in Prader-Willi Syndrome. The change lowers the minimum enrollment age from 10 to 7 years for U.S. participants.
The randomized, double-blind, placebo-controlled HERO study plans to enroll 90 patients across the U.S., Australia, Canada, the U.K. and South Korea, measuring change in Hyperphagia Questionnaire for Clinical Trials scores at Week 12 as the primary endpoint. Enrollment is described as progressing steadily, with topline data targeted for the third quarter of 2026.
Aardvark Therapeutics, Inc. filed a current report to note that on January 12, 2026 it updated its corporate presentation. The presentation, dated January 2026, is intended for meetings with investors, analysts and other stakeholders and will also be posted on the company’s website.
The updated corporate presentation is furnished as Exhibit 99.1 and is incorporated by reference into the Other Events section. The company states the presentation is current as of January 12, 2026 and disclaims any obligation to update this material in the future.
Aardvark Therapeutics, Inc. reported an insider share purchase by its Chief Financial Officer, Nelson Sun. On 12/11/2025, he bought 3,000 shares of common stock in an open-market transaction coded "P" at a price of $14.40 per share. After this transaction, he beneficially owns 108,484 shares of Aardvark Therapeutics common stock in direct ownership.
Aardvark Therapeutics, Inc. reported an insider share purchase by its Chief Executive Officer, who is also a director and 10% owner. On 12/11/2025, the insider bought 7,000 shares of common stock at a price of $14.485 per share. Following this transaction, the insider beneficially owned 1,551,613 common shares directly and 1,474,028 common shares indirectly through a spouse, according to the filing.
Aardvark Therapeutics (AARD) filed its Q3 2025 10‑Q, reporting a net loss of $16.3 million for the quarter and $40.0 million year‑to‑date. Operating expenses rose as the company advanced its pipeline, with Q3 research and development at $13.7 million and general and administrative at $4.0 million.
Liquidity strengthened after the February 2025 IPO, which raised approximately $87.5 million net. As of September 30, 2025, cash, cash equivalents and short‑term investments totaled $126.4 million, which management believes supports operations for at least one year after issuance and, based on current plans, into 2027. Total assets were $133.2 million and stockholders’ equity was $122.4 million.
The company is running the Phase 3 HERO trial of ARD‑101 in Prader‑Willi syndrome, initiated in December 2024 with enrollment underway since Q2 2025. In October 2025, eligibility was expanded by lowering the minimum age to 10 years. Topline HERO data are anticipated in Q3 2026. Shares outstanding were 21,745,265 as of September 30, 2025; 21,773,272 as of November 3, 2025.
Aardvark Therapeutics, Inc. furnished a Form 8-K to announce a press release with financial results for the third quarter ended September 30, 2025, along with pipeline and business updates. The press release is provided as Exhibit 99.1, dated November 13, 2025.
The company states the information in Item 2.02 (including Exhibit 99.1) is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference except as specifically noted. The filing also includes the Cover Page Interactive Data File as Exhibit 104. Aardvark’s common stock (AARD) is listed on The Nasdaq Stock Market LLC.
Aardvark Therapeutics filed an 8-K announcing it hosted an investor webinar on November 5, 2025 to review its ARD-101 and ARD-201 programs and its ObesityWeek 2025 presentations. The slide deck used is posted on the company’s website and is filed as Exhibit 99.1. The presentation is current as of November 5, 2025, and the company disclaims any obligation to update the material.
Aardvark Therapeutics (AARD) furnished an update under Regulation FD about new scientific disclosures at ObesityWeek 2025. The company presented two posters: “TAS2R Agonist ARD-101 Attenuates Weight Gain in Mice and Reduces Hunger in Adults with Obesity” and “An Isoflavonoid Modulator of Oxidative Metabolism with Therapeutic Potential in Obesity and Diabetes.” It also announced an investor webinar on November 5, 2025 covering ARD-101, ARD-201, and the conference data.
The materials are provided as Exhibits 99.1, 99.2, and 99.3 and are furnished, not filed, under the Exchange Act.
Aardvark Therapeutics (AARD) reported an insider option exercise by its Chief Operating Officer. On 10/15/2025, the officer exercised stock options (code M) to acquire 1,250 shares of common stock at an exercise price of $4.24 per share, held directly. Following the transaction, 40,052 derivative securities (stock options) remained beneficially owned.
The option carries an expiration date of 07/20/2034. Per the footnote, 1/48th vested on 07/27/2024 and continues vesting in equal monthly installments, subject to continuous service.